Evidence map›Paper›PMID 26308339›Full record

ArticlePloS one2015

Design of a Vitronectin-Based Recombinant Protein as a Defined Substrate for Differentiation of Human Pluripotent Stem Cells into Hepatocyte-Like Cells.

Masato Nagaoka, Motohiro Kobayashi, Chie Kawai, Sunil K Mallanna, Stephen A Duncan

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Cell sources for in vitro human liver cell culture models.Experimental biology and medicine (Maywood, N.J.) · 2016
    Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Masato NagaokaTenure-track Program for Innovative Research, University of Fukui, Yoshida-gun, Fukui, Japan; Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, Wisconsin, United States of America.
Motohiro KobayashiDivision of Tumor Pathology, Department of Pathological Sciences, Faculty of Medical Sciences, University of Fukui, Yoshida-gun, Fukui, Japan.
Chie KawaiTenure-track Program for Innovative Research, University of Fukui, Yoshida-gun, Fukui, Japan.
Sunil K MallannaDepartment of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, Wisconsin, United States of America.
Stephen A DuncanDepartment of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, Wisconsin, United States of America.
Medical College of Wisconsin · USUniversity of Fukui · JP

Funding

iPS-derived hepatocytes for interrogation of lipid phenotypesU01HG006398 · NHGRI · UNIVERSITY OF PENNSYLVANIA · PI RADER, DANIEL JAMES · 2011 to 2015
$8.6M
TRANSCRIPTIONAL REGULAT OF MAMMALIAN HEPATIC DEVELOPMENTR01DK055743 · NIDDK · MEDICAL COLLEGE OF WISCONSIN · PI DUNCAN, STEPHEN A · 2000 to 2014
$4.6M
Molecular Basis of Human Hepatic Progenitor Cell FormationR01DK102716 · NIDDK · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI DUNCAN, STEPHEN A · 2014 to 2022
$3.8M
Modeling liver metabolism with patient-specific iPS derived hepatocytesRC1DK087377 · NIDDK · MEDICAL COLLEGE OF WISCONSIN · PI DUNCAN, STEPHEN A, GROMPE, MARKUS · 2009 to 2010
$999k
Identification of Pathways Regulating Hepatocyte Differentiation from iPS CellsR21HD082570 · NICHD · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI DUNCAN, STEPHEN A · 2015 to 2016
$409k
NHGRI NIH HHS HG006398NHGRI NIH HHS U01 HG006398NICHD NIH HHS R21 HD082570NIDDK NIH HHS DK087377NIDDK NIH HHS DK102716NIDDK NIH HHS DK55743NIDDK NIH HHS R01 DK055743NIDDK NIH HHS R01 DK102716NIDDK NIH HHS RC1 DK087377
6 · The paper itself

Abstract

Maintenance and differentiation of human pluripotent stem cells (hPSCs) usually requires culture on a substrate for cell adhesion. A commonly used substratum is Matrigel purified from Engelbreth-Holm-Swarm sarcoma cells, and consists of a complex mixture of extracellular matrix proteins, proteoglycans, and growth factors. Several studies have successfully induced differentiation of hepatocyte-like cells from hPSCs. However, most of these studies have used Matrigel as a cell adhesion substrate, which is not a defined culture condition. In an attempt to generate a substratum that supports undifferentiated properties and differentiation into hepatic lineage cells, we designed novel substrates consisting of vitronectin fragments fused to the IgG Fc domain. hPSCs adhered to these substrates via interactions between integrins and the RGD (Arg-Gly-Asp) motif, and the cells maintained their undifferentiated phenotypes. Using a previously established differentiation protocol, hPSCs were efficiently differentiated into mesendodermal and hepatic lineage cells on a vitronectin fragment-containing substrate. We found that full-length vitronectin did not support stable cell adhesion during the specification stage. Furthermore, the vitronectin fragment with the minimal RGD-containing domain was sufficient for differentiation of human induced pluripotent stem cells into hepatic lineage cells under completely defined conditions that facilitate the clinical application of cells differentiated from hPSCs.

Indexed as

Cell DifferentiationAnimalsBlotting, WesternCell AdhesionCell Culture TechniquesCells, CulturedCollagenDrug CombinationsEmbryonic Stem CellsFlow CytometryHepatocytesHumansLamininMiceMice, SCIDPluripotent Stem CellsCollagenDrug CombinationsLamininmatrigelProteoglycansRecombinant ProteinsRNA, MessengerVitronectin

Identifiers

PMID26308339
PMCPMC4550348
OpenAlexW1899328592

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.